JP2007511212A - 新規アデノウイルス、それをコードする核酸及びその使用 - Google Patents
新規アデノウイルス、それをコードする核酸及びその使用 Download PDFInfo
- Publication number
- JP2007511212A JP2007511212A JP2006538818A JP2006538818A JP2007511212A JP 2007511212 A JP2007511212 A JP 2007511212A JP 2006538818 A JP2006538818 A JP 2006538818A JP 2006538818 A JP2006538818 A JP 2006538818A JP 2007511212 A JP2007511212 A JP 2007511212A
- Authority
- JP
- Japan
- Prior art keywords
- adenovirus
- protein
- promoter
- nucleic acid
- tumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 241000701161 unidentified adenovirus Species 0.000 title claims abstract description 652
- 150000007523 nucleic acids Chemical class 0.000 title claims description 199
- 102000039446 nucleic acids Human genes 0.000 title claims description 171
- 108020004707 nucleic acids Proteins 0.000 title claims description 171
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 365
- 102000004169 proteins and genes Human genes 0.000 claims abstract description 267
- 101710199711 Early E1A protein Proteins 0.000 claims abstract description 98
- 210000004027 cell Anatomy 0.000 claims description 471
- 206010028980 Neoplasm Diseases 0.000 claims description 242
- 241000700605 Viruses Species 0.000 claims description 203
- 230000010076 replication Effects 0.000 claims description 184
- 230000014509 gene expression Effects 0.000 claims description 158
- 239000013598 vector Substances 0.000 claims description 131
- 239000003795 chemical substances by application Substances 0.000 claims description 81
- 230000002074 deregulated effect Effects 0.000 claims description 78
- 239000003814 drug Substances 0.000 claims description 67
- 230000022131 cell cycle Effects 0.000 claims description 56
- 201000011510 cancer Diseases 0.000 claims description 51
- 229940079593 drug Drugs 0.000 claims description 51
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 38
- 210000001519 tissue Anatomy 0.000 claims description 38
- 238000011282 treatment Methods 0.000 claims description 38
- 201000010099 disease Diseases 0.000 claims description 36
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 claims description 36
- 239000000824 cytostatic agent Substances 0.000 claims description 35
- RTKIYFITIVXBLE-QEQCGCAPSA-N trichostatin A Chemical compound ONC(=O)/C=C/C(/C)=C/[C@@H](C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-QEQCGCAPSA-N 0.000 claims description 35
- 229960004768 irinotecan Drugs 0.000 claims description 34
- 238000004519 manufacturing process Methods 0.000 claims description 29
- RTKIYFITIVXBLE-UHFFFAOYSA-N Trichostatin A Natural products ONC(=O)C=CC(C)=CC(C)C(=O)C1=CC=C(N(C)C)C=C1 RTKIYFITIVXBLE-UHFFFAOYSA-N 0.000 claims description 27
- 210000000056 organ Anatomy 0.000 claims description 27
- 230000003612 virological effect Effects 0.000 claims description 27
- 230000001613 neoplastic effect Effects 0.000 claims description 23
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 22
- 239000003112 inhibitor Substances 0.000 claims description 22
- 108020004459 Small interfering RNA Proteins 0.000 claims description 20
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 18
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 18
- 230000001404 mediated effect Effects 0.000 claims description 18
- 229960000975 daunorubicin Drugs 0.000 claims description 17
- 230000001965 increasing effect Effects 0.000 claims description 17
- 230000001105 regulatory effect Effects 0.000 claims description 17
- 108010057856 Adenovirus E2 Proteins Proteins 0.000 claims description 15
- 230000002950 deficient Effects 0.000 claims description 15
- 108091023037 Aptamer Proteins 0.000 claims description 14
- 208000026310 Breast neoplasm Diseases 0.000 claims description 14
- 230000006037 cell lysis Effects 0.000 claims description 13
- 230000001419 dependent effect Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- 206010006187 Breast cancer Diseases 0.000 claims description 12
- 230000001276 controlling effect Effects 0.000 claims description 12
- 239000003534 dna topoisomerase inhibitor Substances 0.000 claims description 12
- 230000007246 mechanism Effects 0.000 claims description 12
- 229940044693 topoisomerase inhibitor Drugs 0.000 claims description 12
- 230000006907 apoptotic process Effects 0.000 claims description 11
- 238000000338 in vitro Methods 0.000 claims description 11
- 208000023958 prostate neoplasm Diseases 0.000 claims description 11
- 108090000994 Catalytic RNA Proteins 0.000 claims description 9
- 102000053642 Catalytic RNA Human genes 0.000 claims description 9
- 108010033040 Histones Proteins 0.000 claims description 9
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 9
- 108700025716 Tumor Suppressor Genes Proteins 0.000 claims description 9
- 239000013543 active substance Substances 0.000 claims description 9
- 108091092562 ribozyme Proteins 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 102000044209 Tumor Suppressor Genes Human genes 0.000 claims description 8
- 230000000692 anti-sense effect Effects 0.000 claims description 8
- 230000001939 inductive effect Effects 0.000 claims description 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 8
- 230000005855 radiation Effects 0.000 claims description 8
- -1 DX-895If Chemical compound 0.000 claims description 7
- 239000004037 angiogenesis inhibitor Substances 0.000 claims description 7
- 229940121369 angiogenesis inhibitor Drugs 0.000 claims description 7
- 230000001085 cytostatic effect Effects 0.000 claims description 7
- INVTYAOGFAGBOE-UHFFFAOYSA-N entinostat Chemical compound NC1=CC=CC=C1NC(=O)C(C=C1)=CC=C1CNC(=O)OCC1=CC=CN=C1 INVTYAOGFAGBOE-UHFFFAOYSA-N 0.000 claims description 7
- OHRURASPPZQGQM-GCCNXGTGSA-N romidepsin Chemical compound O1C(=O)[C@H](C(C)C)NC(=O)C(=C/C)/NC(=O)[C@H]2CSSCC\C=C\[C@@H]1CC(=O)N[C@H](C(C)C)C(=O)N2 OHRURASPPZQGQM-GCCNXGTGSA-N 0.000 claims description 7
- BWDQBBCUWLSASG-MDZDMXLPSA-N (e)-n-hydroxy-3-[4-[[2-hydroxyethyl-[2-(1h-indol-3-yl)ethyl]amino]methyl]phenyl]prop-2-enamide Chemical compound C=1NC2=CC=CC=C2C=1CCN(CCO)CC1=CC=C(\C=C\C(=O)NO)C=C1 BWDQBBCUWLSASG-MDZDMXLPSA-N 0.000 claims description 6
- 230000009471 action Effects 0.000 claims description 6
- NCNRHFGMJRPRSK-MDZDMXLPSA-N belinostat Chemical compound ONC(=O)\C=C\C1=CC=CC(S(=O)(=O)NC=2C=CC=CC=2)=C1 NCNRHFGMJRPRSK-MDZDMXLPSA-N 0.000 claims description 6
- 229960003094 belinostat Drugs 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 6
- 210000004962 mammalian cell Anatomy 0.000 claims description 6
- 229940002612 prodrug Drugs 0.000 claims description 6
- 239000000651 prodrug Substances 0.000 claims description 6
- 230000003362 replicative effect Effects 0.000 claims description 6
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 5
- 241000699670 Mus sp. Species 0.000 claims description 5
- 206010029098 Neoplasm skin Diseases 0.000 claims description 5
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 5
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 5
- 239000002246 antineoplastic agent Substances 0.000 claims description 5
- 229940127093 camptothecin Drugs 0.000 claims description 5
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 5
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 5
- 229960005420 etoposide Drugs 0.000 claims description 5
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims description 5
- 239000003475 metalloproteinase inhibitor Substances 0.000 claims description 5
- 201000002528 pancreatic cancer Diseases 0.000 claims description 5
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims description 5
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims description 5
- VEEGZPWAAPPXRB-BJMVGYQFSA-N (3e)-3-(1h-imidazol-5-ylmethylidene)-1h-indol-2-one Chemical compound O=C1NC2=CC=CC=C2\C1=C/C1=CN=CN1 VEEGZPWAAPPXRB-BJMVGYQFSA-N 0.000 claims description 4
- FJHBVJOVLFPMQE-QFIPXVFZSA-N 7-Ethyl-10-Hydroxy-Camptothecin Chemical compound C1=C(O)C=C2C(CC)=C(CN3C(C4=C([C@@](C(=O)OC4)(O)CC)C=C33)=O)C3=NC2=C1 FJHBVJOVLFPMQE-QFIPXVFZSA-N 0.000 claims description 4
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 claims description 4
- 241000283690 Bos taurus Species 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 241000282472 Canis lupus familiaris Species 0.000 claims description 4
- 241000283707 Capra Species 0.000 claims description 4
- 241000282326 Felis catus Species 0.000 claims description 4
- 206010020843 Hyperthermia Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 241001494479 Pecora Species 0.000 claims description 4
- 241000700159 Rattus Species 0.000 claims description 4
- 206010062129 Tongue neoplasm Diseases 0.000 claims description 4
- 108010067390 Viral Proteins Proteins 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 230000036031 hyperthermia Effects 0.000 claims description 4
- 229920001184 polypeptide Polymers 0.000 claims description 4
- VHXNKPBCCMUMSW-FQEVSTJZSA-N rubitecan Chemical compound C1=CC([N+]([O-])=O)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VHXNKPBCCMUMSW-FQEVSTJZSA-N 0.000 claims description 4
- 229950009213 rubitecan Drugs 0.000 claims description 4
- 229960000303 topotecan Drugs 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 206010046766 uterine cancer Diseases 0.000 claims description 4
- JWOGUUIOCYMBPV-GMFLJSBRSA-N (3S,6S,9S,12R)-3-[(2S)-Butan-2-yl]-6-[(1-methoxyindol-3-yl)methyl]-9-(6-oxooctyl)-1,4,7,10-tetrazabicyclo[10.4.0]hexadecane-2,5,8,11-tetrone Chemical compound N1C(=O)[C@H](CCCCCC(=O)CC)NC(=O)[C@H]2CCCCN2C(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-GMFLJSBRSA-N 0.000 claims description 3
- JTDYUFSDZATMKU-UHFFFAOYSA-N 6-(1,3-dioxo-2-benzo[de]isoquinolinyl)-N-hydroxyhexanamide Chemical compound C1=CC(C(N(CCCCCC(=O)NO)C2=O)=O)=C3C2=CC=CC3=C1 JTDYUFSDZATMKU-UHFFFAOYSA-N 0.000 claims description 3
- 229940123587 Cell cycle inhibitor Drugs 0.000 claims description 3
- 241000283086 Equidae Species 0.000 claims description 3
- 208000022072 Gallbladder Neoplasms Diseases 0.000 claims description 3
- 206010061968 Gastric neoplasm Diseases 0.000 claims description 3
- 241000282412 Homo Species 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- JWOGUUIOCYMBPV-UHFFFAOYSA-N OT-Key 11219 Natural products N1C(=O)C(CCCCCC(=O)CC)NC(=O)C2CCCCN2C(=O)C(C(C)CC)NC(=O)C1CC1=CN(OC)C2=CC=CC=C12 JWOGUUIOCYMBPV-UHFFFAOYSA-N 0.000 claims description 3
- 108010082820 apicidin Proteins 0.000 claims description 3
- 229930186608 apicidin Natural products 0.000 claims description 3
- 201000005616 epidermal appendage tumor Diseases 0.000 claims description 3
- 208000014018 liver neoplasm Diseases 0.000 claims description 3
- 230000003211 malignant effect Effects 0.000 claims description 3
- 208000025402 neoplasm of esophagus Diseases 0.000 claims description 3
- 239000008194 pharmaceutical composition Substances 0.000 claims description 3
- 230000019491 signal transduction Effects 0.000 claims description 3
- 201000008753 synovium neoplasm Diseases 0.000 claims description 3
- 208000025421 tumor of uterus Diseases 0.000 claims description 3
- 108700026220 vif Genes Proteins 0.000 claims description 3
- 208000018084 Bone neoplasm Diseases 0.000 claims description 2
- 206010019695 Hepatic neoplasm Diseases 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 210000004102 animal cell Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 210000003527 eukaryotic cell Anatomy 0.000 claims description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 2
- 241000700198 Cavia Species 0.000 claims 2
- 241000282887 Suidae Species 0.000 claims 2
- 102000001253 Protein Kinase Human genes 0.000 claims 1
- 208000023974 pharynx neoplasm Diseases 0.000 claims 1
- 108060006633 protein kinase Proteins 0.000 claims 1
- 108010048626 Y-Box-Binding Protein 1 Proteins 0.000 description 407
- 102100022224 Y-box-binding protein 1 Human genes 0.000 description 405
- 210000004940 nucleus Anatomy 0.000 description 183
- 230000037430 deletion Effects 0.000 description 80
- 238000012217 deletion Methods 0.000 description 80
- 208000015181 infectious disease Diseases 0.000 description 57
- 239000013612 plasmid Substances 0.000 description 51
- 239000000047 product Substances 0.000 description 48
- 108700020796 Oncogene Proteins 0.000 description 46
- 210000004881 tumor cell Anatomy 0.000 description 45
- 108700019146 Transgenes Proteins 0.000 description 44
- 230000000694 effects Effects 0.000 description 41
- 102000043276 Oncogene Human genes 0.000 description 36
- 239000002245 particle Substances 0.000 description 32
- 230000027455 binding Effects 0.000 description 30
- 238000000034 method Methods 0.000 description 30
- 241001135569 Human adenovirus 5 Species 0.000 description 29
- 108020004414 DNA Proteins 0.000 description 28
- 238000010367 cloning Methods 0.000 description 28
- 230000009089 cytolysis Effects 0.000 description 28
- 239000002609 medium Substances 0.000 description 26
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 26
- 238000013461 design Methods 0.000 description 24
- 239000000523 sample Substances 0.000 description 24
- 150000001413 amino acids Chemical class 0.000 description 23
- 150000001875 compounds Chemical class 0.000 description 23
- 108700005077 Viral Genes Proteins 0.000 description 22
- 230000001413 cellular effect Effects 0.000 description 22
- 239000012634 fragment Substances 0.000 description 22
- 230000029812 viral genome replication Effects 0.000 description 21
- 208000009956 adenocarcinoma Diseases 0.000 description 20
- 230000006870 function Effects 0.000 description 20
- 108010049024 Viral Oncogene Proteins Proteins 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 230000004807 localization Effects 0.000 description 18
- 230000032258 transport Effects 0.000 description 18
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 17
- 210000000805 cytoplasm Anatomy 0.000 description 17
- 201000008808 Fibrosarcoma Diseases 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 16
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 15
- 230000004913 activation Effects 0.000 description 15
- 210000003855 cell nucleus Anatomy 0.000 description 15
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 14
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 14
- 241000282414 Homo sapiens Species 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 13
- 239000002773 nucleotide Substances 0.000 description 13
- 206010041823 squamous cell carcinoma Diseases 0.000 description 13
- 101710114676 E1B 55 kDa protein Proteins 0.000 description 12
- 238000001415 gene therapy Methods 0.000 description 12
- 230000006698 induction Effects 0.000 description 12
- 239000012528 membrane Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 12
- 125000003729 nucleotide group Chemical group 0.000 description 12
- 238000013518 transcription Methods 0.000 description 12
- 230000035897 transcription Effects 0.000 description 12
- 125000003275 alpha amino acid group Chemical group 0.000 description 11
- 230000000340 anti-metabolite Effects 0.000 description 11
- 229940100197 antimetabolite Drugs 0.000 description 11
- 239000002256 antimetabolite Substances 0.000 description 11
- 238000003776 cleavage reaction Methods 0.000 description 11
- 230000036457 multidrug resistance Effects 0.000 description 11
- 201000008968 osteosarcoma Diseases 0.000 description 11
- 230000007017 scission Effects 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 208000001258 Hemangiosarcoma Diseases 0.000 description 10
- 208000018142 Leiomyosarcoma Diseases 0.000 description 10
- 239000013078 crystal Substances 0.000 description 10
- 238000003235 crystal violet staining Methods 0.000 description 10
- 239000000835 fiber Substances 0.000 description 10
- 238000001727 in vivo Methods 0.000 description 10
- 238000011534 incubation Methods 0.000 description 10
- 201000001441 melanoma Diseases 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 208000003200 Adenoma Diseases 0.000 description 9
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 9
- 206010016629 fibroma Diseases 0.000 description 9
- 210000004379 membrane Anatomy 0.000 description 9
- 201000003076 Angiosarcoma Diseases 0.000 description 8
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
- 108091034117 Oligonucleotide Proteins 0.000 description 8
- 108050002653 Retinoblastoma protein Proteins 0.000 description 8
- 102000040945 Transcription factor Human genes 0.000 description 8
- 108091023040 Transcription factor Proteins 0.000 description 8
- 239000003550 marker Substances 0.000 description 8
- 230000030648 nucleus localization Effects 0.000 description 8
- 108091008819 oncoproteins Proteins 0.000 description 8
- 230000002441 reversible effect Effects 0.000 description 8
- 230000014616 translation Effects 0.000 description 8
- 229930185603 trichostatin Natural products 0.000 description 8
- 101150082674 E2 gene Proteins 0.000 description 7
- 102000001301 EGF receptor Human genes 0.000 description 7
- 108060006698 EGF receptor Proteins 0.000 description 7
- 101000956263 Homo sapiens Uncharacterized protein C19orf48 Proteins 0.000 description 7
- 229930012538 Paclitaxel Natural products 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 7
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 7
- 238000002105 Southern blotting Methods 0.000 description 7
- 102100038573 Uncharacterized protein C19orf48 Human genes 0.000 description 7
- 238000003556 assay Methods 0.000 description 7
- 108010006025 bovine growth hormone Proteins 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 239000003966 growth inhibitor Substances 0.000 description 7
- 230000002458 infectious effect Effects 0.000 description 7
- 201000010260 leiomyoma Diseases 0.000 description 7
- 201000006512 mast cell neoplasm Diseases 0.000 description 7
- 208000006971 mastocytoma Diseases 0.000 description 7
- 229960001592 paclitaxel Drugs 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 230000002829 reductive effect Effects 0.000 description 7
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 7
- 238000013519 translation Methods 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- 206010001233 Adenoma benign Diseases 0.000 description 6
- 208000005243 Chondrosarcoma Diseases 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 108700026244 Open Reading Frames Proteins 0.000 description 6
- 108010017842 Telomerase Proteins 0.000 description 6
- 230000000120 cytopathologic effect Effects 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 230000010534 mechanism of action Effects 0.000 description 6
- 230000000174 oncolytic effect Effects 0.000 description 6
- 208000003154 papilloma Diseases 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 102100033350 ATP-dependent translocase ABCB1 Human genes 0.000 description 5
- 241000709687 Coxsackievirus Species 0.000 description 5
- 108060001084 Luciferase Proteins 0.000 description 5
- 108010047230 Member 1 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 5
- 102000048850 Neoplasm Genes Human genes 0.000 description 5
- 108700019961 Neoplasm Genes Proteins 0.000 description 5
- 206010033128 Ovarian cancer Diseases 0.000 description 5
- 102100039120 Retinoblastoma-like protein 1 Human genes 0.000 description 5
- 108050002592 Retinoblastoma-like protein 1 Proteins 0.000 description 5
- 230000018199 S phase Effects 0.000 description 5
- 101710183280 Topoisomerase Proteins 0.000 description 5
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 5
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 239000003623 enhancer Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 239000003102 growth factor Substances 0.000 description 5
- 108020004999 messenger RNA Proteins 0.000 description 5
- 239000002207 metabolite Substances 0.000 description 5
- 238000009126 molecular therapy Methods 0.000 description 5
- 230000002018 overexpression Effects 0.000 description 5
- 108091008146 restriction endonucleases Proteins 0.000 description 5
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 5
- 238000002560 therapeutic procedure Methods 0.000 description 5
- 206010044412 transitional cell carcinoma Diseases 0.000 description 5
- 241000894006 Bacteria Species 0.000 description 4
- 108020004705 Codon Proteins 0.000 description 4
- 208000002699 Digestive System Neoplasms Diseases 0.000 description 4
- 102000001388 E2F Transcription Factors Human genes 0.000 description 4
- 108010093502 E2F Transcription Factors Proteins 0.000 description 4
- 206010024612 Lipoma Diseases 0.000 description 4
- 206010025323 Lymphomas Diseases 0.000 description 4
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 4
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 4
- 102000005741 Metalloproteases Human genes 0.000 description 4
- 108010006035 Metalloproteases Proteins 0.000 description 4
- 238000000636 Northern blotting Methods 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 4
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 4
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 4
- 229940100198 alkylating agent Drugs 0.000 description 4
- 239000002168 alkylating agent Substances 0.000 description 4
- 230000003321 amplification Effects 0.000 description 4
- 238000002512 chemotherapy Methods 0.000 description 4
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 4
- 229960004316 cisplatin Drugs 0.000 description 4
- 238000001514 detection method Methods 0.000 description 4
- 230000001747 exhibiting effect Effects 0.000 description 4
- 230000002068 genetic effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 208000032839 leukemia Diseases 0.000 description 4
- 230000000394 mitotic effect Effects 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 238000003199 nucleic acid amplification method Methods 0.000 description 4
- 230000026731 phosphorylation Effects 0.000 description 4
- 238000006366 phosphorylation reaction Methods 0.000 description 4
- 230000008488 polyadenylation Effects 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000005945 translocation Effects 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 description 4
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 3
- 108020005345 3' Untranslated Regions Proteins 0.000 description 3
- 102000043966 ABC-type transporter activity proteins Human genes 0.000 description 3
- 108010006533 ATP-Binding Cassette Transporters Proteins 0.000 description 3
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 description 3
- 108091012583 BCL2 Proteins 0.000 description 3
- 229940123780 DNA topoisomerase I inhibitor Drugs 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 description 3
- 206010018338 Glioma Diseases 0.000 description 3
- 239000005089 Luciferase Substances 0.000 description 3
- 101710170181 Metalloproteinase inhibitor Proteins 0.000 description 3
- 208000007727 Muscle Tissue Neoplasms Diseases 0.000 description 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 3
- 206010029260 Neuroblastoma Diseases 0.000 description 3
- 201000004404 Neurofibroma Diseases 0.000 description 3
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 description 3
- 201000000582 Retinoblastoma Diseases 0.000 description 3
- 108091027076 Spiegelmer Proteins 0.000 description 3
- 229940123237 Taxane Drugs 0.000 description 3
- 239000000365 Topoisomerase I Inhibitor Substances 0.000 description 3
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 3
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 108010084938 adenovirus receptor Proteins 0.000 description 3
- 239000011543 agarose gel Substances 0.000 description 3
- 239000002870 angiogenesis inducing agent Substances 0.000 description 3
- 230000002424 anti-apoptotic effect Effects 0.000 description 3
- 230000002238 attenuated effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000021592 benign granular cell tumor Diseases 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 238000004113 cell culture Methods 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000032823 cell division Effects 0.000 description 3
- 230000010261 cell growth Effects 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 229940088598 enzyme Drugs 0.000 description 3
- 229960002949 fluorouracil Drugs 0.000 description 3
- 238000007710 freezing Methods 0.000 description 3
- 230000008014 freezing Effects 0.000 description 3
- 230000009368 gene silencing by RNA Effects 0.000 description 3
- 208000005017 glioblastoma Diseases 0.000 description 3
- 229940022353 herceptin Drugs 0.000 description 3
- 238000001794 hormone therapy Methods 0.000 description 3
- 230000002934 lysing effect Effects 0.000 description 3
- 201000009020 malignant peripheral nerve sheath tumor Diseases 0.000 description 3
- 206010027191 meningioma Diseases 0.000 description 3
- 201000004130 myoblastoma Diseases 0.000 description 3
- 208000007538 neurilemmoma Diseases 0.000 description 3
- 208000029974 neurofibrosarcoma Diseases 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 238000005375 photometry Methods 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 206010039667 schwannoma Diseases 0.000 description 3
- 239000013605 shuttle vector Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000006467 substitution reaction Methods 0.000 description 3
- 238000001356 surgical procedure Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 238000010257 thawing Methods 0.000 description 3
- 239000003053 toxin Substances 0.000 description 3
- 231100000765 toxin Toxicity 0.000 description 3
- 108700012359 toxins Proteins 0.000 description 3
- ILMNSCQOSGKTNZ-NKWVEPMBSA-N (2r)-2-[(1r)-1-(6-aminopurin-9-yl)-2-oxoethoxy]-3-hydroxypropanal Chemical compound NC1=NC=NC2=C1N=CN2[C@H](O[C@H](CO)C=O)C=O ILMNSCQOSGKTNZ-NKWVEPMBSA-N 0.000 description 2
- FVFVNNKYKYZTJU-UHFFFAOYSA-N 6-chloro-1,3,5-triazine-2,4-diamine Chemical group NC1=NC(N)=NC(Cl)=N1 FVFVNNKYKYZTJU-UHFFFAOYSA-N 0.000 description 2
- 108010022579 ATP dependent 26S protease Proteins 0.000 description 2
- 101710197337 Adenovirus death protein Proteins 0.000 description 2
- 102100023635 Alpha-fetoprotein Human genes 0.000 description 2
- 208000005440 Basal Cell Neoplasms Diseases 0.000 description 2
- 206010004146 Basal cell carcinoma Diseases 0.000 description 2
- 101100297347 Caenorhabditis elegans pgl-3 gene Proteins 0.000 description 2
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 206010057248 Cell death Diseases 0.000 description 2
- 108091026890 Coding region Proteins 0.000 description 2
- 102000010091 Cold shock domains Human genes 0.000 description 2
- 108050001774 Cold shock domains Proteins 0.000 description 2
- 108050006400 Cyclin Proteins 0.000 description 2
- 108090000257 Cyclin E Proteins 0.000 description 2
- 102000003909 Cyclin E Human genes 0.000 description 2
- 102000015792 Cyclin-Dependent Kinase 2 Human genes 0.000 description 2
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 2
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102000053602 DNA Human genes 0.000 description 2
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 2
- 230000004543 DNA replication Effects 0.000 description 2
- 102000002045 Endothelin Human genes 0.000 description 2
- 108050009340 Endothelin Proteins 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 description 2
- 101150064015 FAS gene Proteins 0.000 description 2
- 206010053717 Fibrous histiocytoma Diseases 0.000 description 2
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- 206010069698 Langerhans' cell histiocytosis Diseases 0.000 description 2
- 206010025219 Lymphangioma Diseases 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 208000006644 Malignant Fibrous Histiocytoma Diseases 0.000 description 2
- 229930192392 Mitomycin Natural products 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 108091005461 Nucleic proteins Proteins 0.000 description 2
- 208000031839 Peripheral nerve sheath tumour malignant Diseases 0.000 description 2
- 108091000080 Phosphotransferase Proteins 0.000 description 2
- 208000007452 Plasmacytoma Diseases 0.000 description 2
- 208000037062 Polyps Diseases 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 101710101148 Probable 6-oxopurine nucleoside phosphorylase Proteins 0.000 description 2
- 102100036691 Proliferating cell nuclear antigen Human genes 0.000 description 2
- 102000003923 Protein Kinase C Human genes 0.000 description 2
- 108090000315 Protein Kinase C Proteins 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 102000030764 Purine-nucleoside phosphorylase Human genes 0.000 description 2
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 2
- 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 208000034541 Rare lymphatic malformation Diseases 0.000 description 2
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 2
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 2
- 102100022828 Retinoblastoma-like protein 2 Human genes 0.000 description 2
- 108050002651 Retinoblastoma-like protein 2 Proteins 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 206010041067 Small cell lung cancer Diseases 0.000 description 2
- 206010068771 Soft tissue neoplasm Diseases 0.000 description 2
- 208000005718 Stomach Neoplasms Diseases 0.000 description 2
- 108010091105 Subfamily B ATP Binding Cassette Transporter Proteins 0.000 description 2
- 102000018075 Subfamily B ATP Binding Cassette Transporter Human genes 0.000 description 2
- 241000282898 Sus scrofa Species 0.000 description 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 description 2
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- 102100038313 Transcription factor E2-alpha Human genes 0.000 description 2
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 108010078814 Tumor Suppressor Protein p53 Proteins 0.000 description 2
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 2
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 2
- 208000015778 Undifferentiated pleomorphic sarcoma Diseases 0.000 description 2
- 229940122803 Vinca alkaloid Drugs 0.000 description 2
- 208000008383 Wilms tumor Diseases 0.000 description 2
- 229940009456 adriamycin Drugs 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 229940045799 anthracyclines and related substance Drugs 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 229940046836 anti-estrogen Drugs 0.000 description 2
- 230000001833 anti-estrogenic effect Effects 0.000 description 2
- 239000000051 antiandrogen Substances 0.000 description 2
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- MOTJMGVDPWRKOC-QPVYNBJUSA-N atrasentan Chemical compound C1([C@H]2[C@@H]([C@H](CN2CC(=O)N(CCCC)CCCC)C=2C=C3OCOC3=CC=2)C(O)=O)=CC=C(OC)C=C1 MOTJMGVDPWRKOC-QPVYNBJUSA-N 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 210000000234 capsid Anatomy 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229960004397 cyclophosphamide Drugs 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 235000021186 dishes Nutrition 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 229960004679 doxorubicin Drugs 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- ZUBDGKVDJUIMQQ-UBFCDGJISA-N endothelin-1 Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(O)=O)NC(=O)[C@H]1NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@@H](CC=2C=CC(O)=CC=2)NC(=O)[C@H](C(C)C)NC(=O)[C@H]2CSSC[C@@H](C(N[C@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCC(O)=O)C(=O)N2)=O)NC(=O)[C@@H](CO)NC(=O)[C@H](N)CSSC1)C1=CNC=N1 ZUBDGKVDJUIMQQ-UBFCDGJISA-N 0.000 description 2
- 208000003401 eosinophilic granuloma Diseases 0.000 description 2
- 229940082789 erbitux Drugs 0.000 description 2
- 239000000328 estrogen antagonist Substances 0.000 description 2
- 229960005167 everolimus Drugs 0.000 description 2
- 229950009429 exatecan Drugs 0.000 description 2
- ZVYVPGLRVWUPMP-FYSMJZIKSA-N exatecan Chemical compound C1C[C@H](N)C2=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC3=CC(F)=C(C)C1=C32 ZVYVPGLRVWUPMP-FYSMJZIKSA-N 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 208000024519 eye neoplasm Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 210000004996 female reproductive system Anatomy 0.000 description 2
- 206010017758 gastric cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 210000003128 head Anatomy 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 208000029824 high grade glioma Diseases 0.000 description 2
- 201000000284 histiocytoma Diseases 0.000 description 2
- KTUFNOKKBVMGRW-UHFFFAOYSA-N imatinib Chemical compound C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 KTUFNOKKBVMGRW-UHFFFAOYSA-N 0.000 description 2
- 229960002411 imatinib Drugs 0.000 description 2
- 230000000415 inactivating effect Effects 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 206010022498 insulinoma Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 206010024627 liposarcoma Diseases 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000003670 luciferase enzyme activity assay Methods 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 208000025036 lymphosarcoma Diseases 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 201000008806 mesenchymal cell neoplasm Diseases 0.000 description 2
- 229940126170 metalloproteinase inhibitor Drugs 0.000 description 2
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 2
- 229960000485 methotrexate Drugs 0.000 description 2
- 229960004857 mitomycin Drugs 0.000 description 2
- 201000010225 mixed cell type cancer Diseases 0.000 description 2
- 208000029638 mixed neoplasm Diseases 0.000 description 2
- 206010051747 multiple endocrine neoplasia Diseases 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 201000008026 nephroblastoma Diseases 0.000 description 2
- 206010061311 nervous system neoplasm Diseases 0.000 description 2
- 230000025308 nuclear transport Effects 0.000 description 2
- 238000001668 nucleic acid synthesis Methods 0.000 description 2
- 244000309459 oncolytic virus Species 0.000 description 2
- 208000008798 osteoma Diseases 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 208000029211 papillomatosis Diseases 0.000 description 2
- 102000020233 phosphotransferase Human genes 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical class [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 208000029340 primitive neuroectodermal tumor Diseases 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 230000006798 recombination Effects 0.000 description 2
- 238000005215 recombination Methods 0.000 description 2
- 230000000241 respiratory effect Effects 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- BTIHMVBBUGXLCJ-OAHLLOKOSA-N seliciclib Chemical compound C=12N=CN(C(C)C)C2=NC(N[C@@H](CO)CC)=NC=1NCC1=CC=CC=C1 BTIHMVBBUGXLCJ-OAHLLOKOSA-N 0.000 description 2
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical class C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 description 2
- 208000000649 small cell carcinoma Diseases 0.000 description 2
- 208000000587 small cell lung carcinoma Diseases 0.000 description 2
- 210000004872 soft tissue Anatomy 0.000 description 2
- 201000011549 stomach cancer Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 229940063683 taxotere Drugs 0.000 description 2
- 230000002123 temporal effect Effects 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000010415 tropism Effects 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 241001529453 unidentified herpesvirus Species 0.000 description 2
- 230000002485 urinary effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- OGAPHRMCCQCJOE-BNTLRKBRSA-N (1r,2r)-cyclohexane-1,2-diamine;oxalic acid;platinum Chemical compound [Pt].OC(=O)C(O)=O.N[C@@H]1CCCC[C@H]1N OGAPHRMCCQCJOE-BNTLRKBRSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- HBZBAMXERPYTFS-SECBINFHSA-N (4S)-2-(6,7-dihydro-5H-pyrrolo[3,2-f][1,3]benzothiazol-2-yl)-4,5-dihydro-1,3-thiazole-4-carboxylic acid Chemical compound OC(=O)[C@H]1CSC(=N1)c1nc2cc3CCNc3cc2s1 HBZBAMXERPYTFS-SECBINFHSA-N 0.000 description 1
- FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
- HCUOEKSZWPGJIM-YBRHCDHNSA-N (e,2e)-2-hydroxyimino-6-methoxy-4-methyl-5-nitrohex-3-enamide Chemical compound COCC([N+]([O-])=O)\C(C)=C\C(=N/O)\C(N)=O HCUOEKSZWPGJIM-YBRHCDHNSA-N 0.000 description 1
- KSXTUUUQYQYKCR-LQDDAWAPSA-M 2,3-bis[[(z)-octadec-9-enoyl]oxy]propyl-trimethylazanium;chloride Chemical compound [Cl-].CCCCCCCC\C=C/CCCCCCCC(=O)OCC(C[N+](C)(C)C)OC(=O)CCCCCCC\C=C/CCCCCCCC KSXTUUUQYQYKCR-LQDDAWAPSA-M 0.000 description 1
- RNAMYOYQYRYFQY-UHFFFAOYSA-N 2-(4,4-difluoropiperidin-1-yl)-6-methoxy-n-(1-propan-2-ylpiperidin-4-yl)-7-(3-pyrrolidin-1-ylpropoxy)quinazolin-4-amine Chemical compound N1=C(N2CCC(F)(F)CC2)N=C2C=C(OCCCN3CCCC3)C(OC)=CC2=C1NC1CCN(C(C)C)CC1 RNAMYOYQYRYFQY-UHFFFAOYSA-N 0.000 description 1
- CXURGFRDGROIKG-UHFFFAOYSA-N 3,3-bis(chloromethyl)oxetane Chemical compound ClCC1(CCl)COC1 CXURGFRDGROIKG-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102100026802 72 kDa type IV collagenase Human genes 0.000 description 1
- 101710151806 72 kDa type IV collagenase Proteins 0.000 description 1
- 102100021503 ATP-binding cassette sub-family B member 6 Human genes 0.000 description 1
- 241000701242 Adenoviridae Species 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000037540 Alveolar soft tissue sarcoma Diseases 0.000 description 1
- 102400000068 Angiostatin Human genes 0.000 description 1
- 108010079709 Angiostatins Proteins 0.000 description 1
- 101710094856 Apoptin Proteins 0.000 description 1
- 102400000059 Arg-vasopressin Human genes 0.000 description 1
- 101800001144 Arg-vasopressin Proteins 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 description 1
- 238000009020 BCA Protein Assay Kit Methods 0.000 description 1
- 102000051485 Bcl-2 family Human genes 0.000 description 1
- 108700038897 Bcl-2 family Proteins 0.000 description 1
- 206010061692 Benign muscle neoplasm Diseases 0.000 description 1
- 108010006654 Bleomycin Proteins 0.000 description 1
- 208000003170 Bronchiolo-Alveolar Adenocarcinoma Diseases 0.000 description 1
- 102000005367 Carboxypeptidases Human genes 0.000 description 1
- 108010006303 Carboxypeptidases Proteins 0.000 description 1
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 201000000274 Carcinosarcoma Diseases 0.000 description 1
- 206010008342 Cervix carcinoma Diseases 0.000 description 1
- 101710163595 Chaperone protein DnaK Proteins 0.000 description 1
- 201000005262 Chondroma Diseases 0.000 description 1
- 201000009047 Chordoma Diseases 0.000 description 1
- 108091062157 Cis-regulatory element Proteins 0.000 description 1
- 102100031162 Collagen alpha-1(XVIII) chain Human genes 0.000 description 1
- 102100024458 Cyclin-dependent kinase inhibitor 2A Human genes 0.000 description 1
- 108010037462 Cyclooxygenase 2 Proteins 0.000 description 1
- 201000005171 Cystadenoma Diseases 0.000 description 1
- 108010080611 Cytosine Deaminase Proteins 0.000 description 1
- 102000000311 Cytosine Deaminase Human genes 0.000 description 1
- 210000002334 D-cell of pancreatic islet Anatomy 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 238000007400 DNA extraction Methods 0.000 description 1
- 102100033195 DNA ligase 4 Human genes 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 229940124087 DNA topoisomerase II inhibitor Drugs 0.000 description 1
- 102000004163 DNA-directed RNA polymerases Human genes 0.000 description 1
- 108090000626 DNA-directed RNA polymerases Proteins 0.000 description 1
- 101100506443 Danio rerio helt gene Proteins 0.000 description 1
- WEAHRLBPCANXCN-UHFFFAOYSA-N Daunomycin Natural products CCC1(O)CC(OC2CC(N)C(O)C(C)O2)c3cc4C(=O)c5c(OC)cccc5C(=O)c4c(O)c3C1 WEAHRLBPCANXCN-UHFFFAOYSA-N 0.000 description 1
- GUGHGUXZJWAIAS-QQYBVWGSSA-N Daunorubicin hydrochloride Chemical compound Cl.O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 GUGHGUXZJWAIAS-QQYBVWGSSA-N 0.000 description 1
- 102100035784 Decorin Human genes 0.000 description 1
- 108090000738 Decorin Proteins 0.000 description 1
- 101100364969 Dictyostelium discoideum scai gene Proteins 0.000 description 1
- 101100044298 Drosophila melanogaster fand gene Proteins 0.000 description 1
- 101710201734 E3 protein Proteins 0.000 description 1
- 208000001976 Endocrine Gland Neoplasms Diseases 0.000 description 1
- 108010079505 Endostatins Proteins 0.000 description 1
- 206010014967 Ependymoma Diseases 0.000 description 1
- 201000005231 Epithelioid sarcoma Diseases 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 208000006168 Ewing Sarcoma Diseases 0.000 description 1
- 102000015212 Fas Ligand Protein Human genes 0.000 description 1
- 108010039471 Fas Ligand Protein Proteins 0.000 description 1
- 208000007659 Fibroadenoma Diseases 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 102400000921 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 108700039691 Genetic Promoter Regions Proteins 0.000 description 1
- 208000007569 Giant Cell Tumors Diseases 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 description 1
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 1
- 206010019043 Hair follicle tumour benign Diseases 0.000 description 1
- 101710178376 Heat shock 70 kDa protein Proteins 0.000 description 1
- 101710152018 Heat shock cognate 70 kDa protein Proteins 0.000 description 1
- 208000006050 Hemangiopericytoma Diseases 0.000 description 1
- 241000175212 Herpesvirales Species 0.000 description 1
- 102000018802 High Mobility Group Proteins Human genes 0.000 description 1
- 108010052512 High Mobility Group Proteins Proteins 0.000 description 1
- 102000006947 Histones Human genes 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000021519 Hodgkin lymphoma Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000617823 Homo sapiens Solute carrier organic anion transporter family member 6A1 Proteins 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 208000006001 Hypothalamic Neoplasms Diseases 0.000 description 1
- 108020005350 Initiator Codon Proteins 0.000 description 1
- 101710125507 Integrase/recombinase Proteins 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 102000013462 Interleukin-12 Human genes 0.000 description 1
- 108010065805 Interleukin-12 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 102000000588 Interleukin-2 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108020004684 Internal Ribosome Entry Sites Proteins 0.000 description 1
- 101710128836 Large T antigen Proteins 0.000 description 1
- 208000032420 Latent Infection Diseases 0.000 description 1
- 201000004462 Leydig Cell Tumor Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 208000028018 Lymphocytic leukaemia Diseases 0.000 description 1
- 206010025566 Malignant haemangiopericytoma Diseases 0.000 description 1
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 1
- 108010016113 Matrix Metalloproteinase 1 Proteins 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 101100506445 Mus musculus Helt gene Proteins 0.000 description 1
- 101100364971 Mus musculus Scai gene Proteins 0.000 description 1
- 201000004458 Myoma Diseases 0.000 description 1
- 241000232901 Nephroma Species 0.000 description 1
- 208000008846 Neurocytoma Diseases 0.000 description 1
- 208000009277 Neuroectodermal Tumors Diseases 0.000 description 1
- 208000033383 Neuroendocrine tumor of pancreas Diseases 0.000 description 1
- 108091092724 Noncoding DNA Proteins 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 201000010133 Oligodendroglioma Diseases 0.000 description 1
- 108010057576 Papillomavirus E7 Proteins Proteins 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 206010033963 Parathyroid tumour Diseases 0.000 description 1
- 208000033147 Parenteral nutrition-associated cholestasis Diseases 0.000 description 1
- 108010067902 Peptide Library Proteins 0.000 description 1
- 208000009565 Pharyngeal Neoplasms Diseases 0.000 description 1
- 206010034811 Pharyngeal cancer Diseases 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 208000033014 Plasma cell tumor Diseases 0.000 description 1
- 108010022233 Plasminogen Activator Inhibitor 1 Proteins 0.000 description 1
- 102000001938 Plasminogen Activators Human genes 0.000 description 1
- 108010001014 Plasminogen Activators Proteins 0.000 description 1
- 102100039418 Plasminogen activator inhibitor 1 Human genes 0.000 description 1
- 101100335198 Pneumocystis carinii fol1 gene Proteins 0.000 description 1
- 102100038280 Prostaglandin G/H synthase 2 Human genes 0.000 description 1
- 102100028588 Protein ZNRD2 Human genes 0.000 description 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 201000010208 Seminoma Diseases 0.000 description 1
- 208000003274 Sertoli cell tumor Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 102100021991 Solute carrier organic anion transporter family member 6A1 Human genes 0.000 description 1
- 108700025695 Suppressor Genes Proteins 0.000 description 1
- 208000025194 Sweat Gland Neoplasms Diseases 0.000 description 1
- 206010042658 Sweat gland tumour Diseases 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 description 1
- 206010043276 Teratoma Diseases 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 239000004098 Tetracycline Substances 0.000 description 1
- 108091036066 Three prime untranslated region Proteins 0.000 description 1
- 102000006601 Thymidine Kinase Human genes 0.000 description 1
- 108020004440 Thymidine kinase Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 102000005353 Tissue Inhibitor of Metalloproteinase-1 Human genes 0.000 description 1
- 108010031374 Tissue Inhibitor of Metalloproteinase-1 Proteins 0.000 description 1
- 102000005406 Tissue Inhibitor of Metalloproteinase-3 Human genes 0.000 description 1
- 108010031429 Tissue Inhibitor of Metalloproteinase-3 Proteins 0.000 description 1
- 239000000317 Topoisomerase II Inhibitor Substances 0.000 description 1
- 102100040250 Transcription elongation factor A protein-like 1 Human genes 0.000 description 1
- 102100039094 Tyrosinase Human genes 0.000 description 1
- 108060008724 Tyrosinase Proteins 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 102000013532 Uroplakin II Human genes 0.000 description 1
- 108010065940 Uroplakin II Proteins 0.000 description 1
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 108020000999 Viral RNA Proteins 0.000 description 1
- 108010087302 Viral Structural Proteins Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 208000004354 Vulvar Neoplasms Diseases 0.000 description 1
- 201000008629 Zollinger-Ellison syndrome Diseases 0.000 description 1
- 230000009102 absorption Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 108700010877 adenoviridae proteins Proteins 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 108010026331 alpha-Fetoproteins Proteins 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000033115 angiogenesis Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229940045686 antimetabolites antineoplastic purine analogs Drugs 0.000 description 1
- 229940045688 antineoplastic antimetabolites pyrimidine analogues Drugs 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 230000005775 apoptotic pathway Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- FZCSTZYAHCUGEM-UHFFFAOYSA-N aspergillomarasmine B Natural products OC(=O)CNC(C(O)=O)CNC(C(O)=O)CC(O)=O FZCSTZYAHCUGEM-UHFFFAOYSA-N 0.000 description 1
- LMEKQMALGUDUQG-UHFFFAOYSA-N azathioprine Chemical compound CN1C=NC([N+]([O-])=O)=C1SC1=NC=NC2=C1NC=N2 LMEKQMALGUDUQG-UHFFFAOYSA-N 0.000 description 1
- 229960002170 azathioprine Drugs 0.000 description 1
- 230000008275 binding mechanism Effects 0.000 description 1
- 108091008324 binding proteins Proteins 0.000 description 1
- 238000004166 bioassay Methods 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 229960001561 bleomycin Drugs 0.000 description 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 208000023913 breast extraskeletal osteosarcoma Diseases 0.000 description 1
- 201000003149 breast fibroadenoma Diseases 0.000 description 1
- 201000002858 breast osteosarcoma Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000005252 bulbus oculi Anatomy 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001364 causal effect Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 108091092328 cellular RNA Proteins 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 230000002759 chromosomal effect Effects 0.000 description 1
- 239000013599 cloning vector Substances 0.000 description 1
- 230000008045 co-localization Effects 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 230000009918 complex formation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 229960000978 cyproterone acetate Drugs 0.000 description 1
- UWFYSQMTEOIJJG-FDTZYFLXSA-N cyproterone acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 UWFYSQMTEOIJJG-FDTZYFLXSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- NHVNXKFIZYSCEB-XLPZGREQSA-N dTTP Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)[C@@H](O)C1 NHVNXKFIZYSCEB-XLPZGREQSA-N 0.000 description 1
- 229960003901 dacarbazine Drugs 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 229960003668 docetaxel Drugs 0.000 description 1
- VGRSISYREBBIAL-UHFFFAOYSA-N doronine Natural products O1C(=O)C(C(Cl)C)(O)CC(C)C(C)(OC(C)=O)C(=O)OCC2=CCN(C)CCC1C2=O VGRSISYREBBIAL-UHFFFAOYSA-N 0.000 description 1
- 238000002337 electrophoretic mobility shift assay Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 210000002257 embryonic structure Anatomy 0.000 description 1
- 210000003372 endocrine gland Anatomy 0.000 description 1
- 201000011523 endocrine gland cancer Diseases 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 108010030074 endodeoxyribonuclease MluI Proteins 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 201000008815 extraosseous osteosarcoma Diseases 0.000 description 1
- 210000003754 fetus Anatomy 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 229960002074 flutamide Drugs 0.000 description 1
- MKXKFYHWDHIYRV-UHFFFAOYSA-N flutamide Chemical compound CC(C)C(=O)NC1=CC=C([N+]([O-])=O)C(C(F)(F)F)=C1 MKXKFYHWDHIYRV-UHFFFAOYSA-N 0.000 description 1
- 239000004052 folic acid antagonist Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 201000010175 gallbladder cancer Diseases 0.000 description 1
- 201000008361 ganglioneuroma Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- QTQAWLPCGQOSGP-GBTDJJJQSA-N geldanamycin Chemical class N1C(=O)\C(C)=C/C=C\[C@@H](OC)[C@H](OC(N)=O)\C(C)=C/[C@@H](C)[C@@H](O)[C@H](OC)C[C@@H](C)CC2=C(OC)C(=O)C=C1C2=O QTQAWLPCGQOSGP-GBTDJJJQSA-N 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 230000007274 generation of a signal involved in cell-cell signaling Effects 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000002076 hair follicle neoplasm Diseases 0.000 description 1
- 201000010536 head and neck cancer Diseases 0.000 description 1
- 210000003566 hemangioblast Anatomy 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 239000000833 heterodimer Substances 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000002267 hypothalamic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 230000001976 improved effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 210000003000 inclusion body Anatomy 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 102000003898 interleukin-24 Human genes 0.000 description 1
- 108090000237 interleukin-24 Proteins 0.000 description 1
- 201000009019 intestinal benign neoplasm Diseases 0.000 description 1
- 201000002313 intestinal cancer Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000009916 joint effect Effects 0.000 description 1
- 208000022013 kidney Wilms tumor Diseases 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 201000004959 laryngeal benign neoplasm Diseases 0.000 description 1
- 206010023841 laryngeal neoplasm Diseases 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 201000007270 liver cancer Diseases 0.000 description 1
- 230000007762 localization of cell Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 201000006385 lung benign neoplasm Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000012804 lymphangiosarcoma Diseases 0.000 description 1
- 208000003747 lymphoid leukemia Diseases 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 210000004995 male reproductive system Anatomy 0.000 description 1
- 208000012166 male reproductive system neoplasm Diseases 0.000 description 1
- 201000011614 malignant glioma Diseases 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 210000005075 mammary gland Anatomy 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- GLVAUDGFNGKCSF-UHFFFAOYSA-N mercaptopurine Chemical compound S=C1NC=NC2=C1NC=N2 GLVAUDGFNGKCSF-UHFFFAOYSA-N 0.000 description 1
- 229960001428 mercaptopurine Drugs 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960001156 mitoxantrone Drugs 0.000 description 1
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 238000000329 molecular dynamics simulation Methods 0.000 description 1
- 101150062876 mrp gene Proteins 0.000 description 1
- 208000025113 myeloid leukemia Diseases 0.000 description 1
- 230000002071 myeloproliferative effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 208000025440 neoplasm of neck Diseases 0.000 description 1
- 208000025351 nephroma Diseases 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000011580 nude mouse model Methods 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 230000009996 pancreatic endocrine effect Effects 0.000 description 1
- 208000012110 pancreatic exocrine neoplasm Diseases 0.000 description 1
- 208000021262 pancreatic insulin-producing neuroendocrine tumor Diseases 0.000 description 1
- 208000021255 pancreatic insulinoma Diseases 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 201000005528 peripheral nervous system neoplasm Diseases 0.000 description 1
- 210000004786 perivascular cell Anatomy 0.000 description 1
- 238000002823 phage display Methods 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 208000010626 plasma cell neoplasm Diseases 0.000 description 1
- 238000013492 plasmid preparation Methods 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 229940127126 plasminogen activator Drugs 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- CPTBDICYNRMXFX-UHFFFAOYSA-N procarbazine Chemical compound CNNCC1=CC=C(C(=O)NC(C)C)C=C1 CPTBDICYNRMXFX-UHFFFAOYSA-N 0.000 description 1
- 229960000624 procarbazine Drugs 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000003488 releasing hormone Substances 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 210000004176 reticulum cell Anatomy 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 238000009666 routine test Methods 0.000 description 1
- 201000010383 sebaceous gland neoplasm Diseases 0.000 description 1
- 208000011581 secondary neoplasm Diseases 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 229960003787 sorafenib Drugs 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000011895 specific detection Methods 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000027371 sweat gland benign neoplasm Diseases 0.000 description 1
- 206010042863 synovial sarcoma Diseases 0.000 description 1
- 210000002437 synoviocyte Anatomy 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- AYUNIORJHRXIBJ-TXHRRWQRSA-N tanespimycin Chemical compound N1C(=O)\C(C)=C\C=C/[C@H](OC)[C@@H](OC(N)=O)\C(C)=C\[C@H](C)[C@@H](O)[C@@H](OC)C[C@H](C)CC2=C(NCC=C)C(=O)C=C1C2=O AYUNIORJHRXIBJ-TXHRRWQRSA-N 0.000 description 1
- 229950007866 tanespimycin Drugs 0.000 description 1
- 229960000235 temsirolimus Drugs 0.000 description 1
- 229930101283 tetracycline Natural products 0.000 description 1
- 229960002180 tetracycline Drugs 0.000 description 1
- 235000019364 tetracycline Nutrition 0.000 description 1
- 150000003522 tetracyclines Chemical class 0.000 description 1
- 208000008732 thymoma Diseases 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 208000013076 thyroid tumor Diseases 0.000 description 1
- 201000006134 tongue cancer Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- 208000017997 tumor of parathyroid gland Diseases 0.000 description 1
- 208000025444 tumor of salivary gland Diseases 0.000 description 1
- 239000000717 tumor promoter Substances 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 108091000036 uracil phosphoribosyltransferase Proteins 0.000 description 1
- 208000026517 ureter neoplasm Diseases 0.000 description 1
- 201000011476 ureteral benign neoplasm Diseases 0.000 description 1
- 208000024722 urethra neoplasm Diseases 0.000 description 1
- 229960005356 urokinase Drugs 0.000 description 1
- 208000024719 uterine cervix neoplasm Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 208000013139 vaginal neoplasm Diseases 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- 229960004528 vincristine Drugs 0.000 description 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
- 210000003474 viral inclusion body Anatomy 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 201000005102 vulva cancer Diseases 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10332—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2840/00—Vectors comprising a special translation-regulating system
- C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
- C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES
- C12N2840/206—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES having multiple IRES
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Wood Science & Technology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Physics & Mathematics (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10353152 | 2003-11-14 | ||
| DE102004018117 | 2004-04-14 | ||
| PCT/EP2004/012931 WO2005052143A2 (de) | 2003-11-14 | 2004-11-15 | Neue adenoviren, dafür codierende nukleinsäuren und deren verwendung |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Division JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007511212A true JP2007511212A (ja) | 2007-05-10 |
| JP2007511212A5 JP2007511212A5 (https=) | 2008-01-10 |
Family
ID=34635104
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006538818A Pending JP2007511212A (ja) | 2003-11-14 | 2004-11-15 | 新規アデノウイルス、それをコードする核酸及びその使用 |
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011098213A Expired - Fee Related JP5618896B2 (ja) | 2003-11-14 | 2011-04-26 | 新規アデノウイルス、それをコードする核酸及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20060270016A1 (https=) |
| EP (1) | EP1689446B1 (https=) |
| JP (2) | JP2007511212A (https=) |
| CA (1) | CA2590257A1 (https=) |
| WO (1) | WO2005052143A2 (https=) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2008526188A (ja) * | 2004-12-31 | 2008-07-24 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| JP2008526189A (ja) * | 2004-12-31 | 2008-07-24 | ホルム，ペル・ゾンネ | Ｅ１−マイナスアデノウイルス及びその使用 |
| US10155930B2 (en) | 2002-05-27 | 2018-12-18 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10300096B2 (en) | 2003-11-14 | 2019-05-28 | Per Sonne Holm | Use of adenoviruses and nucleic acids that code for said viruses |
| JP2021517119A (ja) * | 2018-03-05 | 2021-07-15 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置 |
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5156392B2 (ja) | 2005-02-03 | 2013-03-06 | トポターゲット ユーケー リミテッド | Ｈｄａｃ阻害剤を用いる併用療法 |
| ATE542527T1 (de) | 2005-05-13 | 2012-02-15 | Topotarget Uk Ltd | Pharmazeutische formulierungen von hdac-hemmern |
| WO2007054719A2 (en) | 2005-11-10 | 2007-05-18 | Topotarget Uk Limited | Histone deacetylase (hdac) inhibitors (pxdlol) for the treatment of cancer alone or in combination with chemotherapeutic agent |
| US20070129290A1 (en) * | 2005-11-18 | 2007-06-07 | Or Yat S | Metabolite derivatives of the HDAC inhibitor FK228 |
| EP2012801A4 (en) | 2006-04-24 | 2009-08-05 | Gloucester Pharmaceuticals Inc | GEMCITABINE COMBINATION THERAPY |
| US8957027B2 (en) | 2006-06-08 | 2015-02-17 | Celgene Corporation | Deacetylase inhibitor therapy |
| AU2007342028B2 (en) * | 2006-12-29 | 2013-06-13 | Celgene Corporation | Purifiction of romidepsin |
| CN101687010A (zh) * | 2006-12-29 | 2010-03-31 | 格洛斯特制药公司 | 制备Romidepsin |
| JP5580043B2 (ja) * | 2007-04-27 | 2014-08-27 | オンコリスバイオファーマ株式会社 | 放射線増感増強剤 |
| US8642809B2 (en) * | 2007-09-25 | 2014-02-04 | Topotarget Uk Ltd. | Methods of synthesis of certain hydroxamic acid compounds |
| ES2536208T3 (es) * | 2008-03-07 | 2015-05-21 | Onxeo Dk, Branch Of Onxeo S.A., France | Métodos de tratamiento que emplean infusión continua prolongada de Belinostat |
| GB0900555D0 (en) * | 2009-01-14 | 2009-02-11 | Topotarget As | New methods |
| HUE026386T2 (en) | 2009-03-02 | 2016-06-28 | Univ California | Tumor-selective adenovirus e1a and e1b mutants |
| NZ605526A (en) | 2010-07-12 | 2015-04-24 | Celgene Corp | Romidepsin solid forms and uses thereof |
| US8859502B2 (en) | 2010-09-13 | 2014-10-14 | Celgene Corporation | Therapy for MLL-rearranged leukemia |
| AU2013202506B2 (en) | 2012-09-07 | 2015-06-18 | Celgene Corporation | Resistance biomarkers for hdac inhibitors |
| AU2013202507B9 (en) | 2012-11-14 | 2015-08-13 | Celgene Corporation | Inhibition of drug resistant cancer cells |
| NZ630311A (en) | 2013-12-27 | 2016-03-31 | Celgene Corp | Romidepsin formulations and uses thereof |
| CN109576231B (zh) * | 2017-09-28 | 2022-03-25 | 北京康万达医药科技有限公司 | 分离的重组溶瘤腺病毒、药物组合物及其在治疗肿瘤和/或癌症的药物中的用途 |
| AU2019294294A1 (en) | 2018-06-25 | 2021-02-11 | Fondazione Telethon Ets | Gene therapy |
| BR112021026193A2 (pt) * | 2019-06-25 | 2022-02-15 | Microbiotix Inc | Composições e métodos para tratar ou prevenir infecções oculares com filociclovir |
| CN116179604B (zh) * | 2022-08-31 | 2025-08-26 | 上海锦斯生物技术有限公司 | 一种降低回复突变频率的重组5型腺病毒载体及其构建方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053711A2 (de) * | 2000-12-28 | 2002-07-11 | Per Sonne Holm | Verwendung des transkriptionsfaktors yb-1 in adenoviralen systemen |
| JP2006512284A (ja) * | 2002-05-27 | 2006-04-13 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE336587T1 (de) * | 1994-06-10 | 2006-09-15 | Genvec Inc | Adenoviren-vektor systeme und zelllinien |
| US5998205A (en) * | 1994-11-28 | 1999-12-07 | Genetic Therapy, Inc. | Vectors for tissue-specific replication |
| DE19929569A1 (de) * | 1999-06-21 | 2000-12-28 | Holm Per Sonne | Mittel zur Behandlung maligner Erkrankungen unter Verwendung des Proteins YB-1 |
| US20030095989A1 (en) * | 2000-12-18 | 2003-05-22 | Irving John M. | Chimeric cytolytic viruses for cancer treatment |
| DE10150945A1 (de) * | 2001-10-16 | 2003-04-17 | Holm Per Sonne | Adenovirale Systeme und deren Anwendungen |
| MXPA05004074A (es) * | 2002-10-15 | 2005-09-20 | Sonne Holm Per | Nuevos adenovirus, acidos nucleicos que los codifican y su uso. |
-
2004
- 2004-11-15 EP EP04803146.2A patent/EP1689446B1/de not_active Expired - Lifetime
- 2004-11-15 JP JP2006538818A patent/JP2007511212A/ja active Pending
- 2004-11-15 WO PCT/EP2004/012931 patent/WO2005052143A2/de not_active Ceased
- 2004-11-15 US US10/579,543 patent/US20060270016A1/en not_active Abandoned
- 2004-11-15 CA CA002590257A patent/CA2590257A1/en not_active Abandoned
-
2010
- 2010-01-20 US US12/690,729 patent/US8586354B2/en not_active Expired - Fee Related
-
2011
- 2011-04-26 JP JP2011098213A patent/JP5618896B2/ja not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002053711A2 (de) * | 2000-12-28 | 2002-07-11 | Per Sonne Holm | Verwendung des transkriptionsfaktors yb-1 in adenoviralen systemen |
| JP2006512284A (ja) * | 2002-05-27 | 2006-04-13 | ホルム，ペル・ゾンネ | アデノウイルスおよびそれをコードしている核酸の新たな使用 |
Cited By (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155930B2 (en) | 2002-05-27 | 2018-12-18 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10538744B2 (en) | 2002-05-27 | 2020-01-21 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10731136B2 (en) | 2002-05-27 | 2020-08-04 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US11268073B2 (en) | 2002-05-27 | 2022-03-08 | Per Sonne Holm | Use of adenovirus and nucleic acids coding therefor |
| US10300096B2 (en) | 2003-11-14 | 2019-05-28 | Per Sonne Holm | Use of adenoviruses and nucleic acids that code for said viruses |
| JP2008526188A (ja) * | 2004-12-31 | 2008-07-24 | ホルム，ペル・ゾンネ | 動物細胞における多剤耐性を逆転させる方法 |
| JP2008526189A (ja) * | 2004-12-31 | 2008-07-24 | ホルム，ペル・ゾンネ | Ｅ１−マイナスアデノウイルス及びその使用 |
| JP2021517119A (ja) * | 2018-03-05 | 2021-07-15 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置 |
| JP2025013934A (ja) * | 2018-03-05 | 2025-01-28 | クリニクム レヒツ デア イザール デア テクニシェン ウニフェルジテート ミュンヘン | 腫瘍溶解性アデノウイルスとｃｄｋ４／６阻害剤との組み合わせによる腫瘍の処置 |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2005052143A2 (de) | 2005-06-09 |
| JP5618896B2 (ja) | 2014-11-05 |
| CA2590257A1 (en) | 2005-06-09 |
| US20060270016A1 (en) | 2006-11-30 |
| EP1689446B1 (de) | 2015-01-07 |
| US20100297731A1 (en) | 2010-11-25 |
| EP1689446A2 (de) | 2006-08-16 |
| WO2005052143A3 (de) | 2005-09-22 |
| US8586354B2 (en) | 2013-11-19 |
| JP2011200234A (ja) | 2011-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5618896B2 (ja) | 新規アデノウイルス、それをコードする核酸及びその使用 | |
| US20220339219A1 (en) | Method for reversing multiple resistance in animal cells | |
| JP5873893B2 (ja) | アデノウイルスおよびそれをコードしている核酸の新たな使用 | |
| AU2010257327B2 (en) | Adenovirus expressing genes in reverse order and use thereof | |
| JP5435871B2 (ja) | Ｅ１−マイナスアデノウイルス及びその使用 | |
| RU2393221C2 (ru) | Аденовирус с обращенной генной экспрессией и его применение |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20071113 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20071113 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20101026 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20101220 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20101228 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20110927 |